2.69

3.46% 0.09

After Hours: 2.69

Vistagen Therapeutics Inc (VTGN)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Vistagen Therapeutics Inc stock is traded at $2.69, with a volume of 205.54K. It is up +3.46% in the last 24 hours and down -10.63% over the past month. Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.

Previous Close:

$2.60

Open:

$2.62

24h Volume:

205.54K

Relative Volume:

1.11

Market Cap:

$72.40M

Revenue:

$1.04M

Net Income/Loss:

$-32.07M

P/E Ratio:

-0.4171

EPS:

-6.4491

Net Cash Flow:

$-26.12M

1W Performance:

+3.07%

1M Performance:

-10.63%

6M Performance:

-34.07%

1Y Performance:

-28.46%

1-Day Range:

$2.58

$2.72

1-Week Range:

$2.48

$2.7889

52-Week Range:

$2.48

$5.86

Vistagen Therapeutics Inc Stock (VTGN) Company Profile

Name

Vistagen Therapeutics Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

650-577-3600

Address

343 ALLERTON AVENUE, SOUTH SAN FRANCISCO

Employee

Twitter

@vistagen

Next Earnings Date

2024-11-07

Latest SEC Filings

VTGN's Discussions on Twitter

Compare VTGN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VTGN Vistagen Therapeutics Inc	2.69	72.40M	1.04M	-32.07M	-26.12M	-6.4491
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-07-23	Upgrade	Jefferies	Hold → Buy
Aug-07-23	Upgrade	Maxim Group	Hold → Buy
Jul-22-22	Downgrade	Jefferies	Buy → Hold
Jul-22-22	Downgrade	Robert W. Baird	Outperform → Neutral
Jul-22-22	Downgrade	William Blair	Outperform → Mkt Perform
May-20-21	Initiated	Robert W. Baird	Outperform
Feb-18-21	Initiated	Jefferies	Buy
Jan-04-21	Upgrade	William Blair	Mkt Perform → Outperform
Jun-27-18	Initiated	Maxim Group	Buy
Feb-08-18	Reiterated	Chardan Capital Markets	Buy
Mar-28-17	Initiated	Maxim Group	Buy

View All

Vistagen Therapeutics Inc Stock (VTGN) Latest News

Nov 27, 2024

Great Point Partners LLC Sells 855,263 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - MarketBeat

Nov 27, 2024

Nov 26, 2024

Analyzing Vistagen Therapeutics (NASDAQ:VTGN) and Daré Bioscience (NASDAQ:DARE) - Defense World

Nov 26, 2024

Nov 21, 2024

Anxiety drug trials keep Stifel optimistic on VistaGen stock's upside potential - Investing.com Canada

Nov 21, 2024

Reviewing Vistagen Therapeutics (NASDAQ:VTGN) and Minerva Neurosciences (NASDAQ:NERV) - Defense World

Nov 21, 2024

Nov 17, 2024

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest Down 18.1% in October - Defense World

Nov 17, 2024

Nov 15, 2024

Great Point Partners LLC Increases Stake in Vistagen Therapeutics Inc - GuruFocus.com

Nov 15, 2024

Citadel Advisors LLC Increases Stake in Vistagen Therapeutics Inc - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Vistagen Therapeutics adds SKDK, GCI Health alum Michelle Peters Wellington - MM+M Online

Nov 14, 2024

Vistagen CEO to Present at Stifel 2024 Healthcare Conference | VTGN Stock News - StockTitan

Nov 14, 2024

Vistagen to Present at the Stifel 2024 Healthcare Conference - Business Wire

Nov 14, 2024

Nov 11, 2024

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2025 Earnings Call Transcript - Insider Monkey

Nov 11, 2024

Q1 Earnings Estimate for VTGN Issued By William Blair - MarketBeat

Nov 11, 2024

Nov 08, 2024